Obesity and Metabolic Syndrome
The number of overweight and obese subjects is growing worldwide in a pandemic manner. Obesity is associated with a couple of other health threating complications like non-alcoholic fatty liver disease (NAFLD), insulin resistance, lipid disorders, inflammation etc., all together increasing the risk of cardiovascular complications and mortality.
Nowadays, treatment and prevention of obesity has raised to one of the major public health challenges, and in more and more countries, obesity becomes accepted as a serious medical challenge. So far, lifestyle modifications and pharmacological interventions have limited therapeutic effects, and only bariatric or metabolic surgery was able to provide sufficient long-term success. Therefore, there is a high demand for new medications for the treatment of obesity and its associated complications.
This webinar will discuss new insights and understandings in the pathways involved in obesity and the metabolic syndrome. In the recent years, numerous new molecular opportunities to interfere with these pathways have been identified. Preclinical and clinical studies will have to ascertain the safety and clinical efficacy of new molecules for their potential to treat obesity and its complications. The aim of this webinar is to provide some new insights in the interaction of visceral adipose tissue and its metabolic and organic implications. Furthermore, we want to give some impressions about exciting new discoveries in the fight against the obesogenic pandemic.
Key Learning Objectives
- Understanding mechanisms in obesity and the metabolic syndrome
- Understanding new treatment opportunities
- Understanding preclinical assessments
- Understanding clinical assessments
